Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609037 | 1.00 | VCP (0.47) | VCPMGLLTNK2TACR1PTGES | |
| SCHEMBL5206636 | 0.84 | KIT (0.49) | VCPMGLLTNK2PTGESACACB | |
| SCHEMBL5202973 | 0.84 | VCP (0.45) | VCPKCNH2PTGIR | |
| SCHEMBL5205247 | 0.84 | VCP (0.45) | VCPKCNH2 | |
| SCHEMBL5206200 | 0.80 | KCNH2 (0.45) | VCPKCNH2 | |
| SCHEMBL5206571 | 0.79 | VCP (0.43) | VCPKCNH2 | |
| SCHEMBL5206599 | 0.78 | GBA1 (0.48) | VCP | |
| SCHEMBL5205206 | 0.77 | CKS1B (0.49) | VCPACACBACACA | |
| SCHEMBL14608992 | 0.77 | KCNH2 (0.47) | VCPKCNH2 | |
| SCHEMBL5205158 | 0.77 | KCNH2 (0.47) | VCPKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2003104255-A2 | SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NPY5R, NPY4R, NPY1R | VCP 3862/4885MGLL 1633/4885TNK2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.